A randomized trial of memantine as treatment for spasticity in multiple sclerosis
or print this bulletin in its original format.
Medical Update Memo
January 11, 2010
Small study reports the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis. Mult Scler. 2009 Dec 22
Small study reports the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks. Eligible MS patients were required to have an Ashworth spasticity rating of 2 or higher in at least one lower extremity muscle group.
Twenty-one subjects were randomized to receive either placebo (ten) or memantine (11) 10 mg twice a day. The primary outcome measure of efficacy was a change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study.
National Research and Programs
Offert en français.
The Multiple Sclerosis Society of Canada is an independent, voluntary health
agency and does not approve, endorse or recommend any specific product or therapy,
but provides information to assist individuals in making their own decisions.